Gastric Bypass for Diabetic Patients or Sleeve: What the Trials Show

The first question a diabetic patient asks before surgery is usually whether the pills can stop, and which operation to ask about. The honest answer is that surgery can put type 2 diabetes into remission, meaning blood sugar returns to target on less medication or none, but it is not a cure. Below are the randomised-trial numbers with their limits, and the decision itself is left to examination and tests.

You may have read of a cure in 80% or even 100% of patients. Those figures appeared in the Egyptian press, including an Al-Ahram report in 2016 and a Youm7 interview in 2019, and neither cited a study or a patient count. Published trials give lower and clearer figures, and those are what we set out here.

"Gastric bypass" here means the classic Roux-en-Y operation. The mini gastric bypass is a different operation, and the International Federation for the Surgery of Obesity agreed to call it MGB-OAGB, so we use that name whenever we mean it.

The question is pressing in Egypt, where the International Diabetes Federation recorded about 13,214,500 adults with diabetes in 2024. The World Health Organization lists excess weight among the risk factors that contribute to type 2 diabetes.

Gastric bypass for diabetic patients: what the randomised trials show

The STAMPEDE trial enrolled 150 patients with type 2 diabetes and a body mass index (BMI) between 27 and 43. At 5 years, remission (HbA1c of 6.0% or lower, with or without medication) was reached by 5% on intensive drug therapy alone, 29% after gastric bypass and 23% after the sleeve. Weight fell by 23% after bypass and 19% after the sleeve.

However, the trial was not designed to compare the two operations directly, so it cannot show that one beats the other. Its clearest message is that both operations produced far more remission than drug therapy alone.

In the Norwegian Oseberg trial of 109 adults (mean BMI 42.3), remission at 5 years was higher after bypass: 50% versus 20% at HbA1c of 6.0% or lower, and 63% versus 30% below 6.5%. It has limits, though. It ran at a single centre, these figures come from a secondary analysis, and 93 of 109 participants (85%) completed follow-up. Read it as the result of a single trial, not settled fact.

Then comes the Finnish SLEEVEPASS trial of 240 patients (mean BMI 44.6). At 10 years, diabetes remission was 26% after the sleeve and 33% after bypass, and the gap was not statistically significant (P = 0.63). Its primary goal was weight loss, not diabetes.

In short, the numbers for gastric bypass in diabetic patients lean its way in one trial and do not separate the two operations in another. This variation in results means no trial settles that one operation suits every patient with diabetes.

The difference between sleeve and gastric bypass: reflux and complications

Reflux is the sleeve's clearest weakness in the trials. In SM-BOSS, with 217 patients, reflux worsened at 5 years in 31.8% after the sleeve versus 6.3% after bypass, and it resolved in 60.4% after bypass versus 25.0% after the sleeve. In SLEEVEPASS, oesophagitis was found in 31% after the sleeve and 7% after bypass.

Over the longer term, 29.9% of sleeve patients needed a revisional operation for weak weight loss or reflux, against 5.5% after bypass, in the SM-BOSS follow-up at 10 years or more.

Bypass has its own price. In Oseberg, symptomatic hypoglycaemia after meals occurred in 28% after bypass versus 2% after the sleeve. In a meta-analysis of ten randomised trials, the risk of vitamin B12 deficiency was higher after bypass (relative risk 1.86), with no clear difference in anaemia, iron or folate deficiency.

As for the mini gastric bypass, the YOMEGA trial found it non-inferior to the classic bypass for weight loss at 5 years, with similar diabetes remission. But clinical reflux appeared in 41% versus 18%, and 8% of its patients were converted to the classic operation. In a pooled comparison of two trials, HbA1c fell further after the mini bypass, but with more absorption problems, and bile was seen in the stomach pouch in 16% of mini bypass patients and in none after the classic one.

Comparison table: sleeve, gastric bypass and mini gastric bypass

These cells summarise trials with different patients and different aims, so do not add the figures together as if they were one trial. Each operation loses on at least one row, which is why the choice depends on the individual case, not on averages.

Who is more likely to reach remission after surgery

Remission is not spread evenly between patients. In a Cleveland Clinic series of 217 patients followed for a median of 6 years, a short diabetes duration predicted long-term remission, and surgery within 5 years of diagnosis was linked to a high remission rate. In a pooled analysis of 16 studies, remission was negatively linked to age, diabetes duration, insulin use and HbA1c, and positively linked to C-peptide, a sign that beta cells are still working.

The DiaRem score gives the most weight to insulin use before surgery. After gastric bypass, 88% of those scoring 0 to 2 reached early remission versus 2% of those scoring 18 to 22. Even so, the long-term accuracy of such scores remains moderate, so they do not replace a doctor's assessment.

Remission may also not last. The 2025 ADA Standards of Care state that 35% to 50% of those who reach remission relapse later. In a study of 4,434 adults after bypass, complete early remission reached 68.2%, and then diabetes returned within 5 years in 35.1% of them, so regular follow-up matters even in remission.

Who may benefit

The 2022 ASMBS and IFSO guidelines recommend metabolic and bariatric surgery at a BMI of 35 or more regardless of other conditions, and advise considering it between 30 and 34.9 with a metabolic disease, and from 27.5 in Asian patients. The 2025 ADA Standards advise considering metabolic surgery for people with diabetes at a BMI of 30 or more (27.5 or more for Asian Americans) if they are good surgical candidates, at high-volume centres with a multidisciplinary team.

An earlier statement from the Second Diabetes Surgery Summit in 2016, backed by 45 societies, said surgery should be considered between 30 and 34.9 when high blood sugar persists despite optimal treatment. These thresholds work by BMI, not by country, so they read the same for an Egyptian resident, an expat in Cairo or a visitor from the Gulf. We found no Egyptian national guideline for them, and the individual decision follows examination.

Who may not be suitable

• Type 1 diabetes: a systematic review of 30 studies and 706 patients found that surgery lowers daily insulin needs and reduces weight but does not usually improve glucose control, with hypoglycaemia and ketoacidosis the main concerns. No operation has been identified as the right one for these patients, and the 2025 ADA Standards give no graded recommendation for them.
• A BMI below the thresholds above: their case falls outside the guideline recommendations quoted earlier.
• Anyone who cannot commit to follow-up: the ADA recommends long-term medical and behavioural support and regular checks of vitamins and nutrition after any surgery.
• People with marked reflux: the SM-BOSS figures count against the sleeve when reflux is already present, so this is discussed before an operation is chosen.

Risks and limitations

In the pooled ARMMS-T2D analysis of four American trials (median follow-up 11 years), anaemia, fractures and digestive symptoms were more common after surgery. Remission was 18.2% after surgery versus 6.2% with medication and lifestyle care at 7 years, and 12.7% versus zero at 12 years. These are lower figures than the ones circulating in the press.

Surgery does not remove the need for follow-up. In STAMPEDE, the only major late surgical complication recorded was one reoperation, but the trials are small, their centres differ, and remission is defined with two different cut-offs (6.0% or 6.5%), so their numbers should not be applied to every patient. No figure here guarantees your own result.

When to seek medical help

Do not stop diabetes tablets or insulin on your own before or after surgery, because the surgical team and your diabetes doctor adjust doses together. The ADA advises assessing and treating suspected hypoglycaemia with dietary changes, so ask for help if you develop symptoms of low blood sugar after meals.

Also see your doctor if reflux worsens or persists, or if you notice signs of anaemia or vitamin deficiency. Do not postpone the regular follow-up and blood tests your team sets after the operation, and in an emergency go to the nearest hospital.

Verdict: the decision comes after examination and tests

An article cannot settle the choice between the sleeve, gastric bypass and mini gastric bypass. The surgeon weighs diabetes duration, insulin use, HbA1c, BMI, reflux and other conditions, and the ability to keep up follow-up, and carries out the necessary examination and tests first. The trials say that the two main operations give more remission than drugs alone, but they do not say which suits each patient, and remission can return, so read the figures as a basis for discussion with your surgeon, not a promise of results. Dr. Yasser performs all three operations, and you will find details on the pages for laparoscopic sleeve gastrectomy, classic gastric bypass, mini gastric bypass and bariatric surgery.

Frequently asked questions

Does gastric bypass cure diabetes?

No one can promise a cure. It is more accurate to say the disease may go into remission, with blood sugar controlled on less medication or none. Remission reached 29% after bypass in STAMPEDE and 33% after 10 years in SLEEVEPASS, and the disease can return later. Your chances depend on diabetes duration, insulin use and examination results, so do not rely on a general percentage.

Can diabetes come back after the operation?

Yes. The 2025 ADA Standards state that 35% to 50% of those who reach remission relapse later. In a study of 4,434 adults, diabetes returned within 5 years in 35.1% of those with complete early remission. This is why HbA1c monitoring stays necessary after surgery, even when medication has been stopped.

Can I stop insulin after surgery?

Insulin use may fall after the operation, but remission is less likely in people who use insulin beforehand, since the DiaRem score gives it the most weight. STAMPEDE recorded a 35% drop in insulin use after bypass and 34% after the sleeve. Doses are changed only by your medical team, so never stop insulin yourself before or after surgery.

Is the operation suitable for type 1 diabetes?

The evidence is weak. A systematic review of 30 studies found that surgery lowers insulin needs and weight but does not usually improve glucose control, with a risk of hypoglycaemia and ketoacidosis. The 2025 ADA Standards give no graded recommendation, so a specialist team decides after examination and tests, and nothing published on type 2 should be assumed to apply.

What BMI is needed for diabetes surgery?

The 2025 ADA Standards advise considering surgery for people with diabetes at a BMI of 30 or more, or 27.5 or more for Asian Americans, if they are good surgical candidates. ASMBS and IFSO recommend it at 35 or more and advise considering it between 30 and 34.9 with a metabolic disease. These are international BMI thresholds, and the individual decision follows examination and tests.

Next step

The right option for your case is only settled after examination and tests. Book a consultation to discuss your case. Prefer Arabic? Book in Arabic. We do not list prices here, because the cost depends on which operation is right for you, and you can ask about it on WhatsApp.

Send your weight and height, or your question, on WhatsApp and Dr. Yasser’s team will reply to set up your consultation.

Medically reviewed by Dr. Yasser Elbasatiny, MBBCh, MSc, MD (Ain Shams), FRCS (Edinburgh), FICS, consultant bariatric, laparoscopic and oncologic surgeon in Cairo.